Board of Directors

Richard Mansell-Jones, Chairman

Robert J. Bertoldi, Executive Director

Miroslaw Izienicki, Non-executive Director

Paul Kennedy, Non-executive Director

Richard C. E. Morgan, Executive Director

 


 

Richard Mansell-Jones, Chairman

Richard Mansell-JonesRichard Mansell-Jones is a former Non-executive Chairman of Amphion, and has great experience of public company leadership and governance. Mr. Mansell-Jones was Non-executive Chairman of Brown, Shipley & Co. Limited from 1992 until 2003. From 1988 until 2000 he was Executive Chairman of J. Bibby & Sons PLC (subsequently Barloworld PLC); from 1992 until 2005 he was a Non-executive Director of Standard Bank London Limited (now Standard Bank PLC), where latterly he served as Chairman of the Audit Committee, and from 2001 until 2006 he was Non-executive Chairman of Millfield Group plc. Furthermore, Mr. Mansell-Jones is a Non-Executive Director of a number of charities, including Burlington Magazines Publications Limited and World Monuments Fund Britain Limited.  

After reading Literae Humaniores at Worcester College, Oxford, he was articled to Price Waterhouse & Co, becoming a Chartered Accountant, before joining N. M. Rothschild & Sons in 1968


 

Robert J. Bertoldi, Executive Director

Robert J. BertoldiPrior to his involvement with the Company, Mr. Bertoldi was a founder President and CFO of Amphion Capital Partners LLC (the predecessor company) and VennWorks LLC. Mr. Bertoldi is also a general partner of Amphion Partners LLC (formerly known as Wolfensohn Partners, LP). Prior to that, he served as Chief Financial Officer for James D. Wolfensohn, Inc. and Hambro America Inc.

He began his career at KPMG and left as a manager in the investment services department. Mr. Bertoldi received a B.A. in Accounting and Economics from Queens College, New York in 1976 and became a Certified Public Accountant in 1978. He is a member of the AICPA and NYSCPA.

Top of page


 

Miroslaw Izienicki, Non-executive Director

Miroslaw IzienickiMr. Izienicki is a career banker with experience of providing high level corporate finance advisory and M&A services, particularly in respect of multi-stakeholder engagements at or near the interface of government and commerce. Mr. Izienicki, after having served as Chief Operating Officer, is currently Senior Adviser to Gamma Finance LLP, a provider of advisory services to the alternative investments industry with a focus on illiquid hedge funds. Previously, he was Managing Director of Fifth Capital Group, the London-based think tank and leadership counsel. Prior to Fifth Capital, he was Head of Corporate Finance / M&A at the London international HQ of The Nikko Securities Co Ltd of Tokyo, one of the largest Japanese houses. Mr. Izienicki is an alumnus of University of Cambridge and UCL, London.

Mr. Izienicki presently holds directorships with Fifth Capital Limited and its subsidiary undertakings Fifth Capital Partners Limited and The Bank of Broad Wealth Limited.

Top of page


 

Paul Kennedy, Non-executive Director

Miroslaw IzienickiPaul Kennedy has an extensive career in the pharmaceutical industry, occupying senior management positions with major pharmaceutical companies as well as working and investing as an entrepreneur in smaller biotechnology companies.

Mr. Kennedy worked as a Marketing Director for seven years at Abbott France and Boots, both in the UK and France, before joining Novo Nordisk France, where he was President for 15 years. Having left Novo Nordisk in 1994, Mr. Kennedy set up his own pharmaceutical company, Laboratoires Murat, which was purchased by Fuisz Technologies Ltd, a Nasdaq-listed drug delivery company, three years later. Mr. Kennedy then worked as Executive Vice President, Operations for Fuisz Technologies in Paris, adding acquisitions in France, Germany and Italy, before the business was sold to Shire plc in 1999. From 1999 to 2004 he worked as an Independent Consultant in the pharmaceutical industry, and in 2004, Mr. Kennedy became President of International Operations at AIM-listed medical diagnostics company Cozart plc. In 2007, Mr. Kennedy became a controlling shareholder and Director of US listed IVAX Diagnostics, Inc, which was subsequently sold to Transasia Bio-Medicals Ltd, India's largest diagnostics company, in September 2010. Mr. Kennedy is currently a director of Venn Life Sciences Holdings plc and has participated as an investor in several AIM IPOs.

Top of page


 

Richard C. E. Morgan, Executive Director

Richard C. E. MorganOver the course of his career, Mr. Morgan has been directly involved in the start-up and development of more than 35 companies in the information technology, healthcare, and biotechnology industries. Mr. Morgan was a founder and CEO of Amphion Capital Partners LLC (the predecessor company to Amphion Innovations). He was also the Managing General Partner of Amphion Partners LLC (formerly known as Wolfensohn Partners, LP) a position which he retains, although the partnership is no longer active.

Before joining Wolfensohn, Mr. Morgan spent 15 years with Schroders plc, a British merchant bank, where he was a member of the board of the merchant bank and head of the Schroder Strategy Group, which he founded. Mr. Morgan, a British citizen, was raised in Kenya and educated in England. He graduated with a B. Engineering First Class Honors from the University of Auckland, New Zealand. In 1982 he completed the Advanced Management Program at the Harvard Business School.

 

Top of page